|
|
 Previous Article | Table of Contents | Next Article 
Therapeutic levels of functional human factor X in rats after
retroviral-mediated hepatic gene therapy
M Le, T Okuyama, SR Cai, SC Kennedy, WM Bowling, MW Flye and KP Ponder
Department of Internal Medicine, Washington University School of Medicine,
St Louis, MO, USA.
Factor X deficiency results in a rare but serious bleeding disorder that
might be treated by expressing a normal factor X gene in patients. We
generated an amphotropic retroviral vector with the human FX cDNA and
delivered it to rat hepatocytes in vivo during liver regeneration. The
human alpha1-antitrypsin promoter was chosen to direct expression because
it was the most efficient of several tested in yielding expression of
alpha1-antitrypsin protein from a retroviral vector in hepatocytes in vivo.
We achieved expression of factor X in four rats at levels sufficient to
maintain hemostasis in humans (10% to 43% of normal). The factor X was
determined to be functional by using a chromogenic substrate assay after
immunoprecipitation with human specific antibodies. Expression of factor X
remained stable for more than 10 months in two rats. It is likely that
expression will be maintained for the life of the animals, because
retroviral vectors integrate into the chromosome and hepatocytes are
long-lived. The high and stable levels of expression achieved using this
liver-specific promoter overcomes one of the two major obstacles to
successful human gene therapy for hemophilia.
Volume 89,
Issue 4,
pp. 1254-1259,
02/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. P. Niemeyer, R. W. Herzog, J. Mount, V. R. Arruda, D. M. Tillson, J. Hathcock, F. W. van Ginkel, K. A. High, and C. D. Lothrop Jr
Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy
Blood,
January 22, 2009;
113(4):
797 - 806.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schuettrumpf, R. W. Herzog, A. Schlachterman, A. Kaufhold, D. W. Stafford, and V. R. Arruda
Factor IX variants improve gene therapy efficacy for hemophilia B
Blood,
March 15, 2005;
105(6):
2316 - 2323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Xu, C. Gao, M. S. Sands, S.-R. Cai, T. C. Nichols, D. A. Bellinger, R. A. Raymer, S. McCorquodale, and K. P. Ponder
Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B
Blood,
May 15, 2003;
101(10):
3924 - 3932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Mount, R. W. Herzog, D. M. Tillson, S. A. Goodman, N. Robinson, M. L. McCleland, D. Bellinger, T. C. Nichols, V. R. Arruda, C. D. Lothrop Jr, et al.
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
Blood,
April 15, 2002;
99(8):
2670 - 2676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Park, K. Ohashi, and M. A. Kay
Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver
Blood,
August 1, 2000;
96(3):
1173 - 1176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Russell and M. A. Kay
Adeno-Associated Virus Vectors and Hematology
Blood,
August 1, 1999;
94(3):
864 - 874.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Duncan, M. E. Hicks, S.-R. Cai, E. M. Brunt, and K. P. Ponder
Embolization of Portal Vein Branches Induces Hepatocyte Replication in Swine: A Potential Step in Hepatic Gene Therapy
Radiology,
February 1, 1999;
210(2):
467 - 477.
[Abstract]
[Full Text]
|
|
|
|
|
